European Society for Medical Oncology Targeted Anticancer Therapies Asia Congress (ESMO TAT Asia) 2026

Hong Kong 12 June 2026 - 14 June 2026

Regulatory approval delays for pembrolizumab & T-DXd in APAC highlight need for benefit-based prioritization

18 Aug 2026 by

A study conducted by the Asia-Pacific Oncology Drug Development Consortium finds substantial variability in regulatory approval delays of pembrolizumab and trastuzumab deruxtecan (T-DXd) across 10 Asia-Pacific (APAC) territories, and a lack of consistent prioritization of high-incidence tumours, high clinical benefit scores or curative treatment intent.

Regulatory approval delays for pembrolizumab & T-DXd in APAC highlight need for benefit-based prioritization

18 Aug 2026

Novel neoantigen identification platform advances prospects of OTS vaccine for breast cancer

31 Jul 2026 by

A novel platform that can identify tumour-specific alternative splicing (AS)–derived neoantigens with high confidence level could potentially overcome key stumbling blocks in cancer neoantigen vaccine development, according to Ms Bui Que Tran Nguyen of the Medical Genetics Institute, Ho Chi Minh City, Vietnam, who presented her team’s findings at ESMO TAT Asia 2026.

Novel neoantigen identification platform advances prospects of OTS vaccine for breast cancer

31 Jul 2026

Can blood type impact ICI efficacy in head and neck cancer?

24 Jul 2026 by

A multi-omics study by researchers from Japan has found that blood type B (BTB) is associated with reduced immune checkpoint inhibitor (ICI) efficacy in first-line (1L) treatment of head and neck squamous cell carcinoma (HNSCC).

Can blood type impact ICI efficacy in head and neck cancer?

24 Jul 2026

Real-world ES SCLC outcomes comparable between phase I trial participation and SoC

24 Jul 2026 by

A single-centre retrospective observational study of 90 patients from Australia with extensive-stage small cell lung cancer (SCLC) shows that phase I clinical trial participation has acceptable safety and survival outcomes comparable to those of standard-of-care (SoC) treatment.

Real-world ES SCLC outcomes comparable between phase I trial participation and SoC

24 Jul 2026

OS data show promise for risvutatug rezetecan in R/R sarcoma

22 Jul 2026 by

Longer-term follow-up of the phase II ARTEMIS-002 trial continues to show promising efficacy of risvutatug rezetecan (ris-rez) in relapsed or refractory (R/R) sarcoma, with median overall survival (OS) reaching about 2 years, according to data presented at ESMO TAT Asia 2026.

OS data show promise for risvutatug rezetecan in R/R sarcoma

22 Jul 2026